Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi Biologics (Cayman)WXIBF -3.45%94 EV-to-EBITDA is 18.36 as of Sep. 22, 2026, which is 71% below its 10-year median of 62.58. GuruFocus rates WXIBF with a GF Score™ of 94/100 and a GF Value™ of $5.41 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 430 Biotechnology companies, WuXi Biologics (Cayman) ranks worse than 63.72% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, WuXi Biologics (Cayman)'s enterprise value is $23,603 Mil.
WuXi Biologics (Cayman)'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $1,286 Mil. Therefore, WuXi Biologics (Cayman)'s EV-to-EBITDA for today is 18.36.
The historical rank and industry rank for WuXi Biologics (Cayman)'s EV-to-EBITDA or its related term are showing as below:
WXIBF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.87 Med: 62.58 Max: 236.16
Current: 22.75
During the past 12 years, the highest EV-to-EBITDA of WuXi Biologics (Cayman) was 236.16. The lowest was 6.87. And the median was 62.58.
WXIBF's EV-to-EBITDA is ranked worse than 63.72% of 430
companies
in the Biotechnology industry
Industry Median: 13.015
vs WXIBF: 22.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
WuXi Biologics (Cayman)'s PE Ratio (TTM) for today is calculated as:
WuXi Biologics (Cayman)'s share price for today is $6.01.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $0.169.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WXIBF vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s EV-to-EBITDA falls into.
WuXi Biologics (Cayman)'s current Enterprise Value is $23,603 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $1,286 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (WXIBF) has a EV-to-EBITDA of 18.36 as of Sep. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on WuXi Biologics (Cayman). This is 71% below median its historical median of 62.58. Over the past decade, WuXi Biologics (Cayman)'s EV-to-EBITDA has ranged from 6.87 to 236.16. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #274 out of 430 companies in the Biotechnology industry, placing it in the top 63.7%.
Is WuXi Biologics (Cayman)'s EV-to-EBITDA too high?
WuXi Biologics (Cayman)'s current EV-to-EBITDA of 18.36 is 71% below median its 10-year median of 62.58. Over the past 10 years, this metric has ranged from a low of 6.87 to a high of 236.16. The Biotechnology industry median EV-to-EBITDA is 13.02. WuXi Biologics (Cayman)'s value of 18.36 is 41.1% above this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #274 out of 430 companies in the Biotechnology industry, which is below the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #274 out of 430 companies for EV-to-EBITDA. This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. WuXi Biologics (Cayman)'s value of 18.36 is 41.1% above this benchmark. Historically, WuXi Biologics (Cayman)'s own EV-to-EBITDA has ranged from 6.87 to 236.16 over the past decade. While the company's 10-year median is 62.58 vs. the industry median of 13.02, WuXi Biologics (Cayman) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current EV-to-EBITDA of 18.36 is 41.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on WuXi Biologics (Cayman). For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current EV-to-EBITDA is 18.36, which is 71% below median its own 10-year median of 62.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.41, compared to a current price of $6.01 — trading 11.1% above its estimated fair value. The current EV-to-EBITDA is 18.36, which is 71% below median its 10-year median of 62.58 and 41.1% above the Biotechnology industry median of 13.02. WuXi Biologics (Cayman)'s overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current EV-to-EBITDA is 18.36 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be overvalued.
The current stock price of $6.01 is trading 11.1% above its estimated GF Value™ of $5.41.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Overvalued.
Key valuation signals for WXIBF:
EV-to-EBITDA: 18.36 (71% below median its 10-year median of 62.58)
GF Value™: $5.41 vs. price of $6.01 (11.1% above fair value)
Industry Position: 41.1% above the Biotechnology median (#274 of 430)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
94GF Score
Get the complete analysis for WXIBF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
